Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure a
Authors
Carlos J. R. Silva (ORCID: https://orcid.org/0000-0001-6211-3295)
Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure a
Carlos J. R. Silva, David Petullo, John Xu, Kathryn Collison et al.
Journal
Therapeutic Advances in Respiratory Disease
Topics
Heme Oxygenase-1 and Carbon Monoxide
article
Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure a
Carlos J. R. Silva, David Petullo, John Xu, Kathryn Collison, Mihir Shah, Mehul Patel, M Gillen, Artur Bednarczyk, Magnus Aurivillius, Jitendar Reddy, Mandeep Jassal, Ibrahim Raphiou, Klementyna Sychowicz, David Han, Ronald Goldwater, Maria Heijer
article en
Abstract
No abstract available for this paper.
Publication Tag
Therapeutic Advances in Respiratory DiseaseVol. 20
Institutions
Waterford Institute (US), AstraZeneca (South Korea) (KR), AstraZeneca (Australia) (AU), PAREXEL International (United States) (US), AstraZeneca (Switzerland) (CH), AstraZeneca (Poland) (PL), AstraZeneca (Finland) (FI), AstraZeneca (Canada) (CA)